Search results
70 Results for 'Diagnostics for Human and Planetary Health'
- Technologies (14)
- Collaborations (4)
- Team (0)
- News (22)
- Pages (0)
- Multimedia (30)
- Publications (0)
- Jobs (0)
- Events (0)
Technologies 14
-
NeoSense: Sepsis Detection in Newborns
NeoSense is a new test that uses a tiny sample of saliva instead of blood, powered by advanced single-molecule detection and AI. -
COPDx: Rapid diagnostic to triage acute exacerbations
A point-of-care test based on new biomarkers to rapidly identify COPD patients who are high risk of acute exacerbations (AEs), determine the cause, and guide treatment. -
Instrument-Free Molecular Diagnostics
A synthetic biology-based molecular diagnostics platform that enables the creation of low-cost, highly accurate tests for non-clinical settings. -
Paper-Based Diagnostics
With the imminent threat of new pandemics and frequent disease outbreaks exemplified by the recent Ebola and Zika epidemics, there is a growing need for low-cost, easily deployable and simple-to-use diagnostic tools. The Wyss Institute has developed paper-based synthetic gene networks as a next generation diagnostic technology for use in global healthcare crises and patient... -
Extracellular Vesicles for Biomarker Detection
A non-invasive method to identify biomarkers of disease across cell types and develop diagnostics and monitoring systems. -
FcMBL: Broad-Spectrum Pathogen Capture for Infectious Disease Diagnosis and Therapy
The Problem Infectious diseases have plagued humanity for millennia, and the pathogens that infect and sicken humans are constantly evolving. Severe infections can cause sepsis, a life-threatening condition in which a patient’s immune system overreacts to the infection. The body starts to attack itself, which can lead to tissue damage, organ failure, and death. Sepsis...
Collaborations 4
-
Brigham-Wyss DxA
The Wyss DxA's clinical partners from Brigham and Women’s Hospital identify the most pressing unmet diagnostic needs, provide access to high-quality patient samples for our Biomarker Discovery Laboratory (BDL) and Brigham-Wyss DxA collaborators, and provide invaluable feedback and guidance on the engineering and validation of cost-effective, sensitive, and specific diagnostic tests. -
Biomarker Discovery Laboratory (BDL)
Bridging the diagnostic gap from biomarker discovery to market-ready test kits and instruments through cutting-edge technology development and clinical collaboration. -
Wyss DxA Industrial Participant Program
As the industry-facing component of the Wyss Diagnostics Accelerator, the Industrial Participant Program is a collaboration hub between healthcare testing companies and the scientific and clinical community within the Wyss ecosystem that seeks to compress the timeframe for bringing new, high-impact, diagnostic technologies to market. -
Wyss Diagnostics Accelerator (DxA)
An initiative to enable the fast creation of diagnostic technologies to solve high-value clinical problems through deep collaborations driven by unmet diagnostic needs.
News 22
Multimedia 30
-
Video/Animation20-ish Questions with David Walt20-ish Questions shows a different side of Wyss Institute faculty, touching on aspects of their personal life, hobbies, interests, as well as their research. This round follows David Walt, a Core Faculty member of the Wyss Institute as well as the Hansjörg Wyss Professor of Biologically Inspired Engineering at Harvard Medical School, a Professor of... -
Video/AnimationCan We Stop Stabbing Babies? – Salivary Diagnostics for Sepsis Screening in the NeonateEvery day, across the neonatal care unit, babies are being stabbed to collect their blood for sepsis tests. Adding to this dismal situation, diagnostics developed to assess sepsis in blood are very inaccurate, leading to the unnecessary prescription of antibiotics. Researchers at the Wyss Institute and Brigham and Women’s Hospital have created a more accurate... -
Video/AnimationInnovating Diagnostics to Improve Clinical Care and Patient OutcomesGuest speaker, Sarah-Beth Perullo, shares the immense difficulty she faced in obtaining a diagnosis for her mysterious symptoms. Her story is a sobering reminder of how frequent patient symptoms are dismissed in the medical field. Credit: Wyss Institute at Harvard University -
Video/AnimationHow can we get diagnostics to patients faster?The Wyss Diagnostics Accelerator (DxA) is an initiative to enable the fast creation of diagnostic technologies to solve high-value clinical problems through deep collaborations driven by unmet diagnostic needs. Credit: Wyss Institute at Harvard University -
Video/AnimationReimagine the World – Volume 2 – Diagnostics AcceleratorTwo clinicians collaborating with the Wyss Diagnostics Accelerator (DxA), Lise Johnson and Craig Hersh, as well as two members of the Wyss DxA Industrial Partnership Program, Nell Meosky Luo and Andy Levin, share how they would Reimagine the World and the personal stories that fuel their passion for the work they are doing. Credit: Wyss... -
Video/AnimationWyss Diagnostics Accelerator – The Industrial Participant ProgramThe Industrial Participant Program (IPP) is a collaboration hub between healthcare testing companies and the scientific and clinical community within the Wyss ecosystem, driven by the Wyss Diagnostics Accelerator (DxA). Members of the IPP share the common goal of fast-tracking diagnostic technologies to meet unmet, critical needs. Credit: Wyss Institute at Harvard University